Bristol-Myers Squibb Co (NYSE:BMY) price on current trading day, fall -1.39% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $49.76.
A look at the stock’s price movement, the level at last check in today’s session was $50.46, moving within a range at $49.475 and $50.65. The beta value (5-Year monthly) was 0.411. Turning to its 52-week performance, $63.33 and $39.35 were the 52-week high and 52-week low respectively. Overall, BMY moved -17.45% over the past month.
Bristol-Myers Squibb Co’s market cap currently stands at around $101.25 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-05. The company has a Forward Dividend ratio of 2.44, with its dividend yield at 4.90%. As such, investors might be keen on an upside in the stock’s price ahead of the scheduled earnings report.
Analysts have a consensus estimate of 10.74B for the company’s revenue for the quarter, with a low and high estimate of 10.01B and 11.3B respectively. The average forecast suggests down to a -9.50% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 45.79B, representing a -5.19% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that BMY is a 50% Sell. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
14 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 9 analyst(s) rate the stock as a Hold, 5 recommend BMY as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
BMY’s current price about -13.86% and -14.26% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 24.44, while 7-day volatility ratio is 6.81% and 3.59% in the 30-day chart. Further, Bristol-Myers Squibb Co (BMY) has a beta value of 0.45, and an average true range (ATR) of 2.22. Analysts have given the company’s stock an average 52-week price target of $61, forecast between a low of $61 and high of $61. Looking at the price targets, the low is -22.59% off recent price level in today’s trading while to achieve the yearly target high, it has to move -22.59%. Nonetheless, investors will most likely welcome a -22.59% jump to $61 which is the analysts’ median price.
If we refocus on Bristol-Myers Squibb Co (NYSE:BMY), historical trading data shows that trading volumes averaged 14.97 over the past 10 days and 12.38 million over the past 3 months. The company’s latest data on shares outstanding shows there are 2.03 billion shares.
The 0.08% of Bristol-Myers Squibb Co’s shares are in the hands of company insiders while institutional holders own 79.74% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 37.01 million on 2025-03-14, giving us a short ratio of 2.91. The data shows that as of 2025-03-14 short interest in Bristol-Myers Squibb Co (BMY) stood at 182.0 of shares outstanding, with shares short rising to 25.59 million registered in 2025-02-14. Current price change has pushed the stock -12.02% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BMY stock continues to rise going into the next quarter.
